Deep brain stimulation (DBS) devices, on the market for 20 years, have enabled the successful treatment of more than 100,000 patients worldwide with debilitating and increasingly prevalent neurological disorders such as Parkinson's disease (PD), essential tremor, dystonia, and epilepsy. But despite two decades of clinical and real-world experience, the full potential of the "brain pacemaker" market is just beginning to emerge, thanks to aggressive research and development efforts by the big players in this space. Over the past few months, new long-term data have been released that will help fuel growth in this market as two cardiac and neurotechnology device giants – St. Jude Medical Inc. and Boston Scientific Corp. – prepare to challenge worldwide neuromodulation leader Medtronic PLC with competitive, next-generation DBS systems. (Also see Also see "Neuromodulation Market: Innovation Brings High-Growth Rewards" - Medtech Insight, 27 March, 2013. and Also see "Emerging Peripheral Nerve Technologies Draw New Competitors To Neuromodulation Market" - Medtech Insight, 26 April, 2013.).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?